NRX Pharmaceuticals, Inc.

NRXPWSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1719406

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	$0.00	—	—	—	—
Research and Development Expense	$13.4M	$17.0M	$20.3M	$10.6M	—
Operating Expenses	$27.8M	$44.3M	$115.8M	$51.4M	$713.2K
Operating Income (Loss)	-$27.8M	-$44.3M	-$115.8M	-$51.4M	-$713.2K
Interest Expense	—	$120.0K	$18.0K	$56.0K	—
Nonoperating Income (Expense)	-$2.3M	$4.6M	$22.7M	-$390.0K	$1.2M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	—	—	-$93.1M	-$51.8M	$492.6K
Income Tax Expense (Benefit)	$0.00	—	—	—	$84.2K

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$7.3M	$25.8M	$32.7M	$2.9M	$32.1M
Assets, Current	$6.9M	$25.8M	$32.7M	$2.9M	$69.5K
Cash and Cash Equivalents, at Carrying Value	$4.6M	$20.1M	$27.6M	—	—
Accounts Receivable, after Allowance for Credit Loss, Current	—	—	—	$831.0K	—
Liabilities	$19.0M	$18.4M	$11.9M	$46.7M	$2.6M
Liabilities, Current	$19.0M	$15.6M	$11.9M	$46.2M	—
Long-term Debt	—	$10.5M	—	—	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$21.7M	-$39.8M	-$37.7M	-$2.3M	-$792.7K
Net Cash Provided by (Used in) Investing Activities	-$3.0K	-$10.0K	-$7.0K	-$2.0K	$40.2M
Net Cash Provided by (Used in) Financing Activities	$6.2M	$32.2M	$63.5M	$3.2M	-$39.5M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)